FLOW was the first randomised controlled trial to evaluate an GLP-1 receptor agonist (RA) in patients living with type 2 diabetes and chronic kidney disease. In this Expert Insights episode, FLOW steering group member Peter Rossing presents key results of the study and also discusses open questions like: Will these effects translate to other incretin-based therapies? And: Will patients without type 2 diabetes benefit as well?